HETANG News: Hetang Venture Capital Solely Invests in Zhitong Tech, Pioneering the 'Medicine-Engineering Integration' 3D Exoscopic Microsurgery Market
AINNOVI
Developer of Microscopic External Vision Surgical Systems
Recently, AINNOVI announced the completion of a multi-million yuan A+ round of financing. This round of financing was exclusively invested by Hotang Venture Capital.
The funds from this round of financing will be mainly used for the domestic and overseas registration applications and market promotion of the full range of surgical and ophthalmic surgical microscopes.
As a key device for refined surgical operations, the surgical microscope has a wide range of clinical applications, covering neurosurgery, otolaryngology, ophthalmology, spinal surgery, plastic surgery, and more. Globally, the industry is undergoing a transition from traditional optical surgical microscopes toThe deep transformation of the "optics + digital + intelligence" integrated platform represents a potential billion-dollar market. In the past, surgeons had to operate by looking down through an eyepiece with a limited field of view, which not only restricted working distance and depth of field but also caused musculoskeletal strain due to prolonged fixed neck and shoulder postures. Today, the integration of micro-external visualization systems with real-time stereoscopic imaging, long working-distance zoom optics, and multi-axis free-positioning supports allows surgeons to perform precise operations on an ultra-high-definition large screen with a broader and deeper surgical field of view. It also supports intraoperative image overlay and navigation fusion, significantly improving the safety and efficiency of minimally invasive precision procedures and advancing the rapid development of functional preservation and accurate restoration in surgery.
AINNOVI with its own brandAINNOVI®: Rapidly Launching 3 Categories and 6 Models of High-End Microscopic Imaging and Intelligent Products, Leading the Mid-to-High-End Surgical Microscope Industry in China. The advanced 3D external microscopic upgrade product has obtained the Class II Innovative Medical Device Registration Certificate in China.It compensates for the shortcomings of traditional optical surgical microscopes in microscopic external visualization, while also addressing the upgrade needs of existing traditional optical surgical microscopes in medical institutions.Not only has it formed commercial partnerships with leading microscope brands, completed installations in over a hundred hospitals in China, but also achieved overseas (European) sales after obtaining the CE certificate.
This YearIn February, AINNOVI's domestically produced surgical microscope, targeting the mid-to-high-end surgical microscopy market, obtained its registration certificate. The product’s "opto-electro-mechanical-computational" technology chain loop has been fully independently developed.This not only demonstrates the team's advanced manufacturing and assembly capabilities in optics and mechanical control but also highlights the technical advantages in the stereoscopic vision technology chain. The independently developed large working distance optical system, flexible electromagnetic lock control system, and ultra-low latency microscopic external viewing system enable the product to rival high-end new products of traditional surgical microscopes.
As AINNOVI's advanced microscopy imaging upgrade products, ophthalmic surgical microscope products, and intelligent microscopy products gradually obtain registration certificates and enter the market, AINNOVI will inject new vitality into the global surgical microscope market. With an entirely new approach to microscopic external visualization, AINNOVI will accelerate the digital and intelligent development trends of the surgical microscope industry, ushering in a new era of intelligent microscopic external visualization. This advancement will support clinical surgeries in neurosurgery, otolaryngology, and spinal surgery, moving towards more refined and precise directions.
For more details, please click [Read Original] below.
The content of this article is reproduced fromArteryNetOfficial Account
About Hetang Ventures
LOTUS POND VENTURE CAPITALReorganized and established in 2014 under the strategic backdrop of Tsinghua University’s promotion of technology transfer, Hotang Ventures is a professional investment management institution primarily focused on early-stage investments in science and technology innovation enterprises. Hotang Ventures concentrates on key fields such as life sciences, medical devices, information technology, and modern manufacturing. It has long been dedicated to investing in innovative enterprises with core hard technologies, while also specializing in incubating investments from scientific and technological achievements by university and top-tier hospital clinical experts. Currently managing nearly 4 billion yuan in funds, Hotang Ventures has invested in over 100 projects, supporting scientists and entrepreneurs with significant research discoveries and technological innovations to bring their results to market, achieving "commercial transformation from 0 to 1." At the same time, it consistently focuses on selecting high-barrier “first-of-its-kind technologies” for early-stage investment. With outstanding performance, Hotang Ventures has received honors such as being ranked in the Top 50 of China’s Early-Stage Investment Institutions by The Financer and the Top 50 of China’s Best Early-Stage Venture Capital Institutions by ChinaVenture.
